Biocon Biologics commercial partner launches psoriatic arthritis injection in Japan Ruchika Sharma21 May 2025 12:29 PM ISTUstekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.
Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Dr Reddy's Labs, Bio-Thera collaborate for proposed Stelara, Simponi biosimilar Ruchika Sharma27 March 2025 2:30 PM ISTHyderabad: Dr Reddy's Laboratories SA, wholly-owned subsidiary of Dr Reddy's Laboratories Ltd. and Bio-Thera Solutions, a commercial-stage...
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics Ruchika Sharma8 March 2025 1:30 PM ISTBengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced the successful results...
Biocon Biologics unveils Yesintek biosimilar to Stelara in US Ruchika Sharma25 Feb 2025 12:31 PM ISTYESINTEK will be available in all the same formulations currently provided by Stelara.
Biocon Biologics gets Japenese nod for Psoriasis Vulgaris injection Ustekinumab BS Ruchika Sharma7 Jan 2025 1:15 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the...
Approval of Biocon Biologics Yesintek recommended by EMA Committee Ruchika Sharma16 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
USFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis, Psoriatic Arthritis Ruchika Sharma2 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the U.S. Food ...
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, Japan Ruchika Sharma29 Aug 2024 12:30 PM ISTBangalore: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, announced today that the...
Johnson & Johnson beat estimates for Q2 profit, revenue Ruchika Sharma18 July 2024 4:53 PM ISTLondon:Johnson & Johnson exceeded expectations in its second-quarter profit and revenue announced on Wednesday, propelled by robust sales of its...
USFDA approves Selarsdi injection for subcutaneous use to treat severe plaque psoriasis, active psoriatic arthritis: Alvotech, Teva Ruchika Sharma17 April 2024 4:18 PM ISTReykjavik: Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., have announced that the U.S. Food and Drug...
Biocon Biologics secures US market entry date for Bmab 1200, a Proposed Biosimilar to Stelara Ruchika Sharma1 March 2024 3:30 PM ISTStelara (Ustekinumab) is a monoclonal antibody medication that prevents abnormal regulation of interleukin IL-12/23 associated immune diseases and has...
